No abstract available.
Intercellular Adhesion Molecule-1* ; Interleukin-6* ; Keratinocytes*

BACKGROUND: The chemical modification of RBC surface antigen has many advantages for safe transfusion practice. We evaluated the change of antibody reactivity to RBC surface antigen before and after glutaraldehyde crosslinking. MATERIALS AND METHODS: The 10 mL of blood were collected from 20 volunteers and were treated by 2-3% glutaraldehyde at 4degrees C. After 30 minute incubation, Agglutinability of various RBC surface antigen (ABO, Rh-C, c, D, E, e) was measured by titration using anti-sera (Green Cross, Korea, Dade, USA), and compared the agglutinability changes before and after glutaraldehyde crosslinking. RESLUTS: The agglutinability of Rh surface antigens (D, C, c, E, e) was disappeared after glutaraldehyde crosslinking. However, ABO antigens (n=20) still showed strong agglutinability against antisera with some decreased. CONCLUSIONS: It would be useful to apply glutaraldehyde crossliked RBCs for rare blood group transfusion practice, if the safety problem were solved.
Antigens, Surface* ; Blood Substitutes ; Glutaral* ; Immune Sera ; Korea ; Volunteers

BACKGROUND: Today, blood group antigens are a strong barrier of safe transfusion. We evaluated the change of agglutinability of antibody to RBC surface antigen before and after activated methoxy polyethylene glycol (mPEG) modification. METHODS: We collected blood from healthy volunteers and the blood were treated by activated mPEG (MW 5,000, Sigma, USA). Agglutinability of RBC was measured using anti-sera (Green Cross, Korea) in ABO and Rh(D) groups, and compared the agglutinability changes before and after mPEG treatment. RESULTS: The agglutinability of Rh(D) surface antigen (n=20) was disappeared after mPEG treatment. However, ABO antigens showed variable agglutinability against antisera, some of which showed no change at all. CONCLUSIONS: In the case of Rh(D) antigen, it would be useful to apply mPEG treated RBCs for clinical use, if the safety problem were solved. But in the case of ABO antigen, the more evaluation of the condition of reaction and the concentration of mPEG should be needed.
Antigens, Surface* ; Blood Group Antigens ; Blood Substitutes ; Healthy Volunteers ; Immune Sera ; Polyethylene Glycols* ; Polyethylene*